Related Experiment Video
Updated: Dec 20, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Lack of antiviral activity of darunavir against SARS-CoV-2
Sandra De Meyer1, Denisa Bojkova2, Jindrich Cinatl2
1Janssen Pharmaceutica NV, Beerse, Belgium.
Objectives:
Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives.
Methods:
Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed.
Results:
DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM).
Conclusions:
Overall, the data do not support the use of DRV for the treatment of COVID-19.
More Related Videos
Related Concept Videos
Subviral Agents
Retroviruses
Viruses with RNA Genomes
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Antimicrobial Effectiveness

